1. A malignant tumor vaccine composition for HLA-A * 0201 positive individuals, comprising the following peptide: a modified peptide based on the WT1 peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2) or the WT1 peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), each is an incomplete peptide of a protein that is a product of the tumor suppressor gene WT1, the modified peptide is immunogenic for HLA-A * 0201 positive individuals, excluding the modified peptide with the sequence SEQ ID NO: 12, 35, 39 and 75.2. A malignant tumor vaccine composition for HLA-A * 0201-positive individuals containing the following peptide: a modified peptide based on the WT1 peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2) or the peptide WT1: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), each is an incomplete peptide of a protein that is a product of the tumor suppressor gene WT1, the modified peptide is immunogenic for HLA-A * 0201 positive individuals, except for the modified peptide with the sequence SEQ ID NO: 12, 35, 39, 52, and 75.3. The composition of claim 1, wherein the modified peptide is a WT1P1G peptide: Gly Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 4), a WT1P1A peptide: Ala Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 5), WT1P1V peptide: Val Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 6), WT1P1L peptide: Leu Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 7), WT1P1I peptide: Ile Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 8), WT1P1M peptide: Met Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 9), WT1P1W peptide: Trp Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 10), WT1P1F peptide: Phe Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 11), WT1P2V peptide: Ser Val Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 13), WT1P2I peptide: Ser Ile Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 15), WT1P2M peptide: Ser Met Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 16), WT1P3L peptide: Ser Leu Leu Glu Gln Gln Tyr Ser Val (SEQ ID NO: 17), peptide WT1P3A: Ser Leu Ala Glu Gln Gln Tyr Se
